| Sign In to gain access to subscriptions and/or personal tools. |
An Automated Image Capture and Quantitation Approach to Identify Proteins Affecting Tumor Cell ProliferationTarget Discovery Department, Sugen, Inc. (A Subsidiary of Pfizer), South San Francisco
Target Discovery Department, Sugen, Inc. (A Subsidiary of Pfizer), South San Francisco
Target Discovery Department, Sugen, Inc. (A Subsidiary of Pfizer), South San Francisco
Target Discovery Department, Sugen, Inc. (A Subsidiary of Pfizer), South San Francisco To facilitate the characterization of proteins that negatively regulate tumor cell proliferation in vitro, the authors have implemented a high-throughput functional assay that measures S-phase progression of tumor cell lines. For 2 tumor cell lines—human melanoma A375 and human lung carcinoma A549—conditions were established using the cyclin-dependent kinase inhibitor, p27kip; the tumor suppressor p53, a kinase-inactive allele of the cell cycle-regulated serine/threonine kinase Aurora2; and the G1/S drug block, aphidicolin. For screening purposes, gene libraries were delivered by adenoviral infection. Cells were fixed and labeled by immunocytochemistry, and an automated image acquisition and analysis package on a Cellomics ArrayScan®II was used to quantify the effects of these treatments on cell proliferation. The assay can be used to identify novel proteins involved in proliferation and serves as a more robust, reproducible, and sensitive alternative to enzyme-linked immunosorbent assay (ELISA)-based technologies.
Key Words: proliferation • BrdU • Cellomics • immunofluorescence
Journal of Biomolecular Screening, Vol. 9, No. 3,
216-222 (2004) This article has been cited by other articles:
|
|
||||||||||||||
 |
|
|
 |
|
Sign In to gain access to subscriptions and/or personal tools.
